Severe Malaria Clinical Trial
Official title:
Treatment of Severe Malaria - An Operational Comparative Study Between Quinine and Artesunate for the Treatment of Severe Malaria in Hospitals and Health Centers of Kinshasa and Lower Congo
The MATIAS study aims to demonstrate through limited scope implementation studies how injectable artesunate may be progressively rolled out nationwide in the Democratic Republic of the Congo as the preferred treatment for severe malaria.
In 2010 the AQUAMAT study demonstrated that the treatment of severe malaria with artesunate in children reduced the case fatality substantially. An overall reduction of 22.5 % of mortality in African children (< 15 years) was reported using injectable artesunate compared to injectable quinine for treatment of severe malaria caused by Plasmodium falciparum. These results with high quality evidence led to a change in the WHO guidelines for the treatment of severe malaria in 2011. The WHO now recommends intravenous artesunate as the treatment of choice for severe malaria in children and adults. In early 2012 the Programme National de Lutte contre of Paludisme (PNLP) of the DRC with support from the relevant ministry departments decided to follow the WHO guidelines and changed the policy for the treatment of severe malaria in children and adults from injectable quinine to injectable artesunate. However, this process is a complex undertaking, requiring many operational and clinical adaptations. In order to support this process, there is a need for on-site operational information on the process and consequences of the switch from quinine to artesunate. The MATIAS study aims to demonstrate through limited scope implementation studies how injectable artesunate may be progressively rolled out nationwide in the Democratic Republic of the Congo as the preferred treatment for severe malaria. ;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01955382 -
Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria
|
Phase 2 | |
| Not yet recruiting |
NCT01122134 -
Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment
|
N/A | |
| Recruiting |
NCT04675931 -
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
|
Phase 2 | |
| Recruiting |
NCT05685875 -
Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
|
||
| Completed |
NCT02451904 -
Severe and Cerebral Malaria Investigated Through Host Metabolomics
|
||
| Completed |
NCT04037332 -
Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
|
||
| Completed |
NCT00341003 -
Severe Malaria and Anti-malarial Drug Resistance in Cambodia
|
N/A | |
| Completed |
NCT01255215 -
Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
|
Phase 1/Phase 2 | |
| Completed |
NCT05140278 -
Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate
|
Phase 2 | |
| Recruiting |
NCT05711485 -
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
|
N/A | |
| Completed |
NCT04473768 -
Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
|
||
| Completed |
NCT04176029 -
Lung Ultrasound in Children With Severe Malaria
|
||
| Recruiting |
NCT06064591 -
Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
|
||
| Recruiting |
NCT04251351 -
Effect of Paracetamol on Kidney Function in Severe Malaria
|
Phase 3 | |
| Completed |
NCT00342043 -
Examination of Protective Factors Against Severe Malaria
|
N/A | |
| Completed |
NCT04516317 -
Very Severe Malaria Treated by Intravenous Artesunate
|